Company Filing History:
Years Active: 2016-2022
Title: Christian Sinzger: Innovator in HCMV Research
Introduction
Christian Sinzger is a notable inventor based in Reutlingen, Germany. He has made significant contributions to the field of medical research, particularly in the area of human cytomegalovirus (HCMV) treatment and prevention. With a total of two patents to his name, Sinzger's work is recognized for its potential impact on public health.
Latest Patents
Sinzger's latest patents include innovative solutions for inhibiting HCMV entry. The first patent focuses on a soluble PDGFR-alpha-Fc chimera, a PDGFR-alpha derived peptide, an anti-PDGFR-alpha antibody, or a PDGFR-alpha antibody fragment. This invention aims to provide methods for treating subjects infected by HCMV and for prophylaxis in those not yet infected. The second patent pertains to the production of dense bodies (DB) from HCMV-infected cells, which includes a pharmaceutical composition containing these dense bodies.
Career Highlights
Throughout his career, Christian Sinzger has worked with prominent companies in the pharmaceutical sector, including Aicuris GmbH & Co. KG and Aicuris Anti-infective Cures GmbH. His work in these organizations has contributed to advancements in anti-infective therapies.
Collaborations
Sinzger has collaborated with esteemed colleagues such as Peter Lischka and Cora Stegmann. These partnerships have fostered a collaborative environment that enhances research and innovation in the field.
Conclusion
Christian Sinzger's contributions to HCMV research through his patents and collaborations highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements in treatment and prevention strategies against HCMV.